| Neoplasms, Nerve Tissue |
NCT02147951: Expanded Access Protocol of Talimogene Laherparepvec for Subjects With Unresected, Stage lllB to IVM1c Melanoma |
|
|
| No Longer Available | 3b | | US | Talimogene Laherparepvec | Amgen | Unresected Stage IIIb to IVM1c Melanoma | | | | |
| Not yet recruiting | 3 | 10500 | Europe | Surgical Excision Margin | Norfolk and Norwich University Hospitals NHS Foundation Trust, Australia & New Zealand Melanoma Trials Group | Melanoma | | | | |
NCT00652990: Sirolimus to Treat Plexiform Neurofibromas in Patients With Neurofibromatosis Type I |
|
|
| Active, not recruiting | 2 | 18 | US | Sirolimus | University of Alabama at Birmingham, National Cancer Institute (NCI) | Neurofibromatosis Type 1, Plexiform Neurofibromas, Paraspinal Plexiform Neurofibromas | 08/14 | 08/14 | | |
| Recruiting | 2 | 18 | US | AZD6244 | National Cancer Institute (NCI) | Optic Glioma, Pilocytic Astrocytoma, Low Grade Glioma, Fibriullary Astrocytoma | 10/16 | 11/18 | | |
NCT01322542: YF476 in Patients With Type II Gastric Carcinoids Associated With Zollinger-Ellison Syndrome |
|
|
| Recruiting | 2 | 30 | US | YF476 | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Carcinoid | 12/17 | 12/17 | | |
OCCLURANDOM, NCT02230176: Antitumor Efficacy of Peptide Receptor Radionuclide Therapy With 177Lutetium -Octreotate Randomized vs Sunitinib in Unresectable Progressive Well-differentiated Neuroendocrine Pancreatic Tumor: First Randomized Phase II |
|
|
| Recruiting | 2 | 80 | Europe | Sunitinib, 177Lu-DOTA0-Tyr3-Octreotate | Gustave Roussy, Cancer Campus, Grand Paris, National Cancer Institute, France, Advanced Accelerator Applications | Pancreatic Neuroendocrine Carcinoma | 10/23 | 10/23 | | |
NCT00436735: Nelfinavir in Treating Patients With Metastatic, Refractory, or Recurrent Solid Tumors |
|
|
| Active, not recruiting | 1 | 45 | US | midazolam hydrochloride, nelfinavir mesylate, gene expression analysis, polymerase chain reaction, protein expression analysis, immunoenzyme technique, immunologic technique, laboratory biomarker analysis, mass spectrometry | National Cancer Institute (NCI) | Colorectal Cancer, Gastrointestinal Carcinoid Tumor, Head and Neck Cancer, Islet Cell Tumor, Lung Cancer, Metastatic Cancer, Neuroendocrine Carcinoma of the Skin, Ovarian Cancer, Pheochromocytoma, Sarcoma, Unspecified Adult Solid Tumor, Protocol Specific | | | | |
| No Longer Available | N/A | | US | CP-675,206 | Pfizer | Advanced Unresectable Melanoma | | | | |
NCT01005537: Cyclophosphamide, Autologous Lymphocytes, and Aldesleukin in Treating Patients With Metastatic Melanoma |
|
|
| No Longer Available | N/A | | US | aldesleukin, therapeutic autologous lymphocytes, cyclophosphamide | Fred Hutchinson Cancer Center, National Cancer Institute (NCI) | Melanoma (Skin) | 10/10 | | | |
NCT00495066: Compassionate Use Trial for Unresectable Melanoma With Ipilimumab |
|
|
| No Longer Available | N/A | | RoW | Ipilimumab | Bristol-Myers Squibb | Melanoma | | | | |
|
|
|
|
|
|
|
|
|
NCT01338389: Influence of Oral Treatment With Citicoline for the Prevention of Radiation Optic Neuropathy in Patients Treated for Uveal Melanomas With Proton Beam Therapy |
|
|
| Completed | N/A | 21 | Europe | CITICOLINE, PLACEBO | Centre Hospitalier Universitaire de Nice, DENSMORE pharmaceuticals | Uveal Melanoma | 06/17 | 06/17 | | |
NCT01728051: Expanded Access Study of Melphalan With Delcath CS-PHP System in Patients With Ocular/Cutaneous Melanoma Mets to Liver |
|
|
| No Longer Available | N/A | | US | Melphalan, Percutaneous Hepatic Perfusion | Delcath Systems Inc. | Metastatic Liver Cancer, Ocular Melanoma, Cutaneous Melanoma | | | | |
DCVax-L EAP, NCT02146066: Expanded Access Protocol for GBM Patients With Already Manufactured DCVax®-L Who Have Screen-Failed Protocol 020221 |
|
|
| Available | N/A | | US | DCVax-L | Northwest Biotherapeutics | GBM, Glioblastoma Multiforme | | | | |
CheckMate 218, NCT02186249: Expanded Access Program With Nivolumab in Combination With Ipilimumab in Patients With Tumors Unable to be Removed by Surgery or Metastatic Melanoma |
|
|
| No Longer Available | N/A | | US, Canada | Nivolumab, Ipilimumab | Bristol-Myers Squibb | Malignant Melanoma | | | | |
|
NCT01980732: 68Ga DOTA-TATE PET/CT in Somatostatin Receptor Positive Tumors |
|
|
| No Longer Available | N/A | | US | 68Ga-DOTA TATE | Andrei Iagaru | Carcinoid Tumors, Islet Cell (Pancreatic NET), Other Neuroendocrine Tumors | | | | |
NCT02083484: Program for Pembrolizumab (MK-3475) in Participants With Metastatic Melanoma Who Have Failed Standard of Care Therapy Including Ipilimumab (MK-3475-030) |
|
|
| No Longer Available | N/A | | NA | Pembrolizumab | Merck Sharp & Dohme LLC | Melanoma | | | | |
|
|
|
| No Longer Available | N/A | | US, Canada, RoW | Nivolumab | Bristol-Myers Squibb | Stage III (Unresectable) or Stage IV Advanced Melanoma | 05/18 | 05/18 | | |
NCT02329002: SPT Screening in Irradiated Hereditary Retinoblastoma Survivors |
|
|
| Recruiting | N/A | 400 | Europe | Magnetic resonance imaging | Amsterdam UMC, location VUmc, ODAS | Retinoblastoma | 10/18 | 10/23 | | |
| Active, not recruiting | N/A | 296 | Europe | | European Organisation for Research and Treatment of Cancer - EORTC | Cutaneous Melanoma | 12/23 | 12/31 | | |
NCT00872391: Hypofractionated Stereotactic Linear Accelerator Radiotherapy of Uveal Melanoma |
|
|
| Recruiting | N/A | 155 | Europe | Hypofractionated linear accelerator radiotherapy | Medical University of Vienna | Uveal Melanoma | 03/24 | | | |
NCT00683319: Observing Young Patients With Ependymoma Undergoing Standard Combination Chemotherapy |
|
|
| Active, not recruiting | N/A | 50 | Europe | carboplatin, cisplatin, cyclophosphamide, methotrexate, vincristine sulfate, adjuvant therapy, cognitive assessment, magnetic resonance imaging, magnetic resonance spectroscopic imaging, quality-of-life assessment | Children's Cancer and Leukaemia Group | Brain and Central Nervous System Tumors, Cognitive/Functional Effects, Long-term Effects Secondary to Cancer Therapy in Children, Ototoxicity | 03/34 | | | |
NCT01438658: Assessing the Clinical Effectiveness of Serum Biomarkers in the Diagnosis of Metastatic Uveal Melanoma |
|
|
| Recruiting | N/A | 250 | RoW | | Hadassah Medical Organization | Uveal Melanoma | 12/40 | 12/40 | | |